Highbridge Capital Management’s Biogen BIIB Stock Holding History

Highbridge Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-700	Closed	-$203K	–	512
2018 Q2	$203K	Sell	700 -900	-56%	-$253K	﹤0.01%	821
2018 Q1	$436K	Sell	1,600 -2,900	-64%	-$900K	0.01%	739
2017 Q4	$1.44M	Buy	4,500 +1,600	+55%	+$513K	0.03%	456
2017 Q3	$905K	Buy	+2,900	New	+$859K	0.01%	636
2017 Q1	–	Sell	-30,000	Closed	-$8.51M	–	1435
2016 Q4	$8.51M	Buy	30,000 +20,000	+200%	+$5.93M	0.15%	175
2016 Q3	$3.13M	Buy	+10,000	New	+$2.96M	0.05%	354
2013 Q3	–	Sell	-7,300	Closed	-$1.57M	–	1270
2013 Q2	$1.57M	Buy	+7,300	New	+$1.56M	0.02%	544

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Highbridge Capital Management's BIIB Position: Q4 2018 in Review

Highbridge Capital Management sold out of Biogen (BIIB) in Q4 2018, closing a stake of 7,491 shares — an estimated $2.65M sold.

Highbridge Capital Management first reported a position in BIIB in Q2 2013 and held it in 15 quarters. The position peaked at $49M in Q4 2014. 1,141 funds tracked by Wall St. Rank hold BIIB as of Q4 2018.

Highbridge Capital Management reported no remaining Biogen position as of Q4 2018 after selling out during the quarter.
Highbridge Capital Management sold 7,491 Biogen shares in Q4 2018, an estimated $2.65M.
Highbridge Capital Management first reported a position in Biogen in Q2 2013 and held it in 15 quarters.
Highbridge Capital Management's Biogen position peaked at $49M in Q4 2014.
1,141 funds tracked by Wall St. Rank held Biogen as of Q4 2018.

Based on Highbridge Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.